Bruker Expands Drug Discovery Capabilities with Majority Investment in MIMETAS and Organ-on-a-Chip Technology
Bruker Corporation has announced a majority investment in MIMETAS B.V., a biotechnology company specializing in organ-on-a-chip platforms and advanced human tissue and disease models for pharmaceutical research and drug development. The strategic investment is expected to broaden Bruker’s portfolio of post-genomic technologies and strengthen its capabilities in human physiology-relevant research models, including Microphysiological Systems (MPS), also known as New Approach Methodologies (NAMs).
The transaction represents an expansion of Bruker’s capabilities beyond traditional analytical and molecular characterization technologies into advanced biological models that more closely replicate aspects of human physiology. By combining MIMETAS’ organ-on-a-chip technology with Bruker’s expertise in proteomics, metabolomics, nuclear magnetic resonance (NMR), preclinical imaging and spatial biology, the companies aim to create more integrated workflows for disease research, therapeutic discovery and preclinical development.
Financial terms of the transaction were not disclosed. MIMETAS will continue operating under its established brand and management following the investment.
Advancing Human-Relevant Models for Drug Discovery
Drug discovery and development increasingly rely on experimental systems that can provide meaningful insights into how potential therapies may behave in the human body. Traditional laboratory models, while valuable, may not always reproduce the complexity of human tissues, organs and disease processes.
Microphysiological Systems have emerged as an important area of research because they are designed to recreate selected aspects of human physiology in controlled laboratory environments. Organ-on-a-chip technologies can incorporate human cells and tissues into microfluidic systems, allowing researchers to examine biological responses under conditions that more closely resemble those found in living organisms.
MIMETAS has developed its technology around this concept. Its platforms enable researchers to investigate disease mechanisms, tissue interactions and drug responses using perfused human tissue models. These systems are designed to support scalable research workflows, making them potentially useful for pharmaceutical and biotechnology companies evaluating large numbers of compounds.
The investment gives Bruker an opportunity to combine these human-relevant models with its existing analytical technologies. Researchers could potentially use organ-on-a-chip systems to generate biological samples and then apply advanced molecular, cellular and spatial characterization tools to understand the resulting responses in greater detail.
Frank H. Laukien, President and Chief Executive Officer of Bruker Corporation, said that human physiology-relevant tissue and disease models are becoming increasingly important for understanding disease biology and evaluating therapeutic candidates.
He noted that MIMETAS’ organ-on-a-chip platforms complement Bruker’s existing capabilities in multiomics, spatial biology and preclinical imaging. According to Bruker, Microphysiological Systems and other NAM technologies have significant potential to become increasingly important components of drug discovery, development and preclinical testing.
MIMETAS’ OrganoPlate Platform
At the center of MIMETAS’ technology portfolio is its OrganoPlate platform, an organ-on-a-chip system designed to combine microfluidic tissue culture with a standard microtiter-plate format.
The platform uses membrane-free microfluidic tissue cultures and is designed to support applications involving imaging, automated laboratory handling and higher-throughput research. By adopting a plate-based format, the technology is intended to integrate more easily with established laboratory workflows and automation systems.
This scalability is particularly relevant to pharmaceutical research, where large numbers of compounds may need to be screened and evaluated. Researchers can potentially use human tissue models to assess biological responses while collecting information about toxicity, efficacy and disease-related mechanisms.
MIMETAS also offers OrganoReady tissue and organoid products, supporting instruments and contract research services. Together, these offerings provide researchers with a broader ecosystem for conducting organ-on-a-chip and human tissue research.
The company’s portfolio includes models designed to represent different biological systems and disease areas, enabling pharmaceutical and biotechnology organizations to explore therapeutic candidates using human-derived experimental models.
Connecting Tissue Models With Multiomics
One of the most important aspects of the Bruker-MIMETAS combination is the potential integration of organ-on-a-chip systems with molecular characterization technologies.
Bruker has extensive capabilities in proteomics, metabolomics, NMR, spatial biology and preclinical imaging. These technologies can provide researchers with detailed information about changes occurring at the molecular and cellular levels.
When combined with human tissue models, such analytical tools could help scientists gain deeper insight into how diseases develop and how therapeutic candidates influence biological pathways.
For example, researchers could expose a human tissue model to a drug candidate and then use molecular profiling technologies to characterize changes in proteins, metabolites or spatial patterns. Such integrated workflows could provide a more comprehensive understanding of drug response than relying on a single type of measurement.
The companies plan to develop product and service workflows that connect MIMETAS’ human model systems with Bruker’s technologies for molecular and cellular characterization.
This approach could potentially help researchers connect observations at the tissue level with molecular mechanisms underlying disease or treatment response.
Supporting Pharmaceutical and Biotechnology Research
Both Bruker and MIMETAS already serve pharmaceutical and biotechnology customers, making their technologies complementary across the drug development process.
MIMETAS’ platforms can provide human tissue and disease models for experimental testing, while Bruker’s technologies can be used to characterize biological responses in greater detail.
The combined capabilities may be particularly valuable during early drug discovery, where researchers must make decisions about which candidates should progress into more advanced stages of development.
A more detailed understanding of therapeutic responses could help researchers identify promising compounds, investigate mechanisms of action and detect potential safety concerns earlier in development.
The approach could also contribute to the development of more sophisticated preclinical testing strategies. As pharmaceutical companies seek to improve the predictive value of laboratory models, technologies that better reflect aspects of human physiology are attracting increasing attention.
Customer Experience Demonstrates Potential
MIMETAS has already established applications for its technology within pharmaceutical research. A senior scientific director at a global pharmaceutical company highlighted the use of the company’s OrganoReady Colon Organoid Model together with its OrganoTEER system in toxicity testing.
According to the customer, the technology has become integrated into the company’s routine toxicity-testing workflow and supports consistent and reproducible data generation.
Such applications demonstrate the potential of organoid and organ-on-a-chip technologies to move beyond experimental research and become part of practical drug development workflows.
The ability to integrate these systems into existing screening and testing processes may be an important factor in broader adoption across pharmaceutical and biotechnology organizations.
Expanding Global Access to Human Tissue Models
MIMETAS co-founders and co-CEOs Paul Vulto and Jos Joore said that joining Bruker creates opportunities to expand the company’s platforms and make advanced human tissue models available to a larger global research community.
They emphasized the potential of combining the company’s OrganoPlate and OrganoReady technologies with Bruker’s molecular and cellular characterization capabilities.
The goal is to create integrated workflows that can support disease research, compound evaluation and drug development.
Such integration could also contribute to the generation of increasingly complex biological datasets. These datasets may become valuable not only for conventional drug discovery but also for the development of artificial intelligence and machine-learning models used in biomedical research.
Potential Role in New Approach Methodologies
The investment also strengthens Bruker’s position in the growing field of New Approach Methodologies.
NAMs encompass a broad range of approaches intended to provide new ways of studying human biology and evaluating the safety and effectiveness of potential therapies. Microphysiological Systems and organ-on-a-chip models are among the technologies being explored as part of this evolving research landscape.
Interest in these approaches is increasing as researchers look for experimental systems that can provide more human-relevant information during drug development.
Bruker’s investment in MIMETAS gives the company exposure to this expanding field while allowing it to connect NAM-based biological models with established analytical and imaging technologies.
Building an Integrated Research Platform
The broader objective of the transaction is to connect human tissue models with advanced molecular, cellular and spatial characterization.
Such an integrated approach could help researchers generate more comprehensive evidence during disease research and drug development. It may also support the creation of high-quality datasets that can inform development decisions and potentially serve as inputs for future AI-based biomedical models.
By combining MIMETAS’ scalable biological models with Bruker’s analytical technologies, the companies aim to provide pharmaceutical and biotechnology researchers with a more connected workflow extending from biological modeling to molecular characterization.
The investment therefore represents more than an expansion of Bruker’s product portfolio. It signals a strategic move toward combining human-relevant experimental systems with advanced technologies for measuring and interpreting biological responses.
As drug developers continue searching for more predictive and scalable approaches to preclinical research, the combination of organ-on-a-chip models, organoids, multiomics and spatial analysis could become increasingly important.
With MIMETAS continuing under its established brand and management, the companies can focus on integrating their complementary capabilities while maintaining the expertise and infrastructure that have supported MIMETAS’ growth.
Although the financial terms of the transaction remain undisclosed, the majority investment establishes a new strategic relationship between Bruker and MIMETAS. The companies are positioned to pursue integrated solutions for disease biology, drug discovery, toxicity testing and therapeutic development, potentially helping researchers generate more human-relevant evidence earlier in the development process.
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels.
In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy, as well as in industrial and cleantech research, and semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, proteomics and multiomics, spatial and single-cell biology, structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
About MIMETAS:
MIMETAS is a global leader in human organ-on-a-chip solutions for drug discovery and development. Through its proprietary OrganoPlate® platform, the company provides predictive human tissue and disease models that help pharmaceutical and biotechnology companies improve decision making across the R&D pipeline, from target validation and disease understanding to efficacy and safety assessment. By combining human-relevant biology, scalable laboratory workflows and deep application expertise, MIMETAS enables customers to generate actionable data that improves clinical translation, accelerates development timelines and supports the transition away from animal testing.
The company’s solutions are used by many of the world’s leading life science organizations to address critical challenges in drug discovery, toxicology, and selection. With operations in North America, Europe and Asia, MIMETAS is committed to advancing human-centric research through innovative products, contract research services and New Approach Methodologies that deliver better science and better outcomes for patients.